🫀 Vedolizumab shines in early Crohn's disease: LOVE-CD phase 4 results
🧪 What was studied — Phase 4 open-label cohort (n=260; 86 early, 174 late Crohn's, 22 centres, Europe). Patients with moderate-severe Crohn’s received IV vedolizumab for 1 year. Comparison: early (<2 years, biologic-naive) vs late (>2 years, prior anti-TNF) disease. Endpoints: dual clinical (CDAI ≤150) and endoscopic (SES-CD <4) remission at weeks 26 & 52; safety.
📈 Key results — Clinical+endoscopic remission achieved in 31.4% (27/86) early vs. 8.6% (15/174) late CD (diff 22.8%, 95% CI 12.6-33.7). Serious adverse events substantially less frequent in early disease (3.5% vs 26.4%), with lower infections, surgery, and malignancy.
📍 What this changes in practice
- Initiate vedolizumab early in biologic-naive Crohn’s for best remission outcomes.
- Expect fewer complications and superior safety in early-stage patients.
- Practical for moderate-severe, ulcerative cases with short disease duration.
🔗 Source — PubMed | DOI
🫀 US real-world data: Very low TB risk for vedolizumab & other advanced therapies in IBD
🔥 Main in 3 points
- Tuberculosis rates on vedolizumab, anti-TNFs, and ustekinumab all <40/100,000 person-years
- No significant difference between drug classes (HR 1.16, 95% CI 0.41–3.31)
- Low TB incidence with all agents in US clinical practice
🧪 Context — US registry study (n=20,705 IBD patients on advanced therapies, 2014–2022). Incidence and comparative risk of TB after biologic/JAK therapy launch.
📍 Practical significance —
- Baseline TB screening remains essential, but overall risk is minimal in low-incidence areas.
- Vedolizumab and other advanced therapies can be safely prescribed without extra TB concern in the US.
🔗 Source — PubMed | DOI
🫀 Genotype-guided IBD management: IL10 variant linked to biologic success
🔥 Main in 3 points
- IL10 rs1800896 variant independently predicts higher remission rates with biologic therapy (aOR = 4.15, 95% CI: 1.49-11.56)
- Genotyping key cytokine SNVs can help individualise IBD therapy
- No such links found for TNFA, TGFB, or IL6 SNVs
🧪 Context — Italian cohort (n=197, CD/UC patients; prospective, 12-months follow-up) on biologics; outcome biochemical remission at 1 year.
📍 Practical significance —
- Consider genetic profiling for patients starting biologics—IL10 rs1800896 status may help predict remission odds and tailor therapy decisions.
🔗 Source — PubMed | DOI
|
